227 results on '"Albright, Charles F."'
Search Results
2. A Novel Suppressor of ras1 in Fission Yeast, byr4, Is a Dosage-Dependent Inhibitor of Cytokinesis
3. Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies
4. Synergistic inhibition of Aβ production by combinations of γ-secretase modulators
5. Discovery and Optimization of Biaryl Alkyl Ethers as a Novel Class of Highly Selective, CNS-Penetrable, and Orally Active Adaptor Protein-2-Associated Kinase 1 (AAK1) Inhibitors for the Potential Treatment of Neuropathic Pain
6. Discovery of (S)-1-((2′,6-Bis(difluoromethyl)-[2,4′-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine (BMS-986176/LX-9211): A Highly Selective, CNS Penetrable, and Orally Active Adaptor Protein-2 Associated Kinase 1 Inhibitor in Clinical Trials for the Treatment of Neuropathic Pain
7. Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of the Oral γ-Secretase Inhibitor BMS-708163 (Avagacestat): Tolerability Profile, Pharmacokinetic Parameters, and Pharmacodynamic Markers
8. A High-Throughput Screen for Receptor Protein Tyrosine Phosphatase–γ Selective Inhibitors
9. A 13-amino Acid Peptide in Three Yeast Glycosyltransferases May be Involved in Dolichol Recognition
10. A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects
11. Synthesis of functionalized derivatives of the gamma-secretase modulator BMS-932481 and identification of its major metabolite
12. [ 3H]BMS-599240 — A novel tritiated ligand for the characterization of BACE1 inhibitors
13. Therapeutic Strategies for Alzheimer’s Disease
14. Methylation-Sensitive Restriction Enzyme Quantitative Polymerase Chain Reaction Enables Rapid, Accurate, and Precise Detection of Methylation Status of the Regulatory T Cell (Treg)-Specific Demethylation Region in Primary Human Tregs
15. γ-Secretase Inhibitors for Alzheimer’s Disease: Balancing Efficacy and Toxicity
16. Robust Pre-Clinical Results and Large-Scale Manufacturing Process for Edit-301: An Autologous Cell Therapy for the Potential Treatment of SCD
17. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat
18. EDIT-301: An Experimental Autologous Cell Therapy Comprising Cas12a-RNP Modified mPB-CD34+ Cells for the Potential Treatment of SCD
19. STRATEGIES TO TARGET CHEMOTHERAPEUTICS TO TUMORS
20. CONTRIBUTORS
21. Identification and Preclinical Evaluation of the Bicyclic Pyrimidine γ-Secretase Modulator BMS-932481
22. Viable mouse gene ablations that robustly alter brain Aβ levels are rare
23. Discovery of furo[2,3-d][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors
24. Amelioration of Alpha-1 Antitrypsin Deficiency Diseases with Genome Editing in Transgenic Mice
25. Response to “Unexpected mutations after CRISPR–Cas9 editing in vivo”
26. Macrocyclic prolinyl acyl guanidines as inhibitors of β-secretase (BACE)
27. Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer’s Mouse Phenotypes
28. The experimental design and data interpretation in “Unexpected mutations after CRISPR–Cas9 editing in vivo” by Schaefer et al. are insufficient to support the conclusions drawn by the authors
29. Discovery of furo[2,3- d ][1,3]thiazinamines as beta amyloid cleaving enzyme-1 (BACE1) inhibitors
30. Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine β-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors
31. Loss of Rhb1, a Rheb-Related GTPase in Fission Yeast, Causes Growth Arrest With a Terminal Phenotype Similar to That Caused by Nitrogen Starvation
32. Targeting the BACE1 Active Site Flap Leads to a Potent Inhibitor That Elicits Robust Brain Aβ Reduction in Rodents
33. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat
34. Passive Immunization with Phospho-Tau Antibodies Reduces Tau Pathology and Functional Deficits in Two Distinct Mouse Tauopathy Models
35. Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitors
36. Monosubstituted γ-lactam and conformationally constrained 1,3-diaminopropan-2-ol transition-state isostere inhibitors of β-secretase (BACE)
37. Synthesis and SAR of indole-and 7-azaindole-1,3-dicarboxamide hydroxyethylamine inhibitors of BACE-1
38. Preparation, Properties, and Uses of Benzeneboronic Acid
39. Organoboron Compounds
40. Preparation, Properties, and Uses of Borate Esters
41. Discovery of S3-Truncated, C-6 Heteroaryl Substituted Aminothiazine β-Site APP Cleaving Enzyme-1 (BACE1) Inhibitors.
42. Discovery of matrix metalloproteases selective and activated peptide–doxorubicin prodrugs as anti-tumor agents
43. Identification and Preclinical Pharmacology of theγ-Secretase Modulator BMS-869780
44. Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease
45. Synthesis and SAR of hydroxyethylamine based phenylcarboxyamides as inhibitors of BACE
46. Pharmacodynamics of Selective Inhibition of γ-Secretase by Avagacestat
47. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ-secretase inhibitor avagacestat
48. Acyl Guanidine Inhibitors of β-Secretase (BACE-1): Optimization of a Micromolar Hit to a Nanomolar Lead via Iterative Solid- and Solution-Phase Library Synthesis
49. Association between GTPase activators for Rho and Ras families
50. Target Selection in Drug Discovery
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.